References
- Akkiz H, Bayram S, Bekar A, et al (2010). Cyclin D1 G870A polymorphism is associated with an increased risk of hepatocellular carcinoma in the Turkish population: casecontrol study. Cancer Epidemiol, 34, 298-302. https://doi.org/10.1016/j.canep.2010.02.011
- Balcerczak E, Pasz-Walczak G, Kumor P, et al (2005). Cyclin D1 protein and CCND1 gene expression in colorectal cancer. Eur J Surg Oncol, 31, 721-6. https://doi.org/10.1016/j.ejso.2005.04.005
- Bizari L, Borim AA, Leite KR, Goncalves Fde T, et al (2006). Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. Cancer Genet Cytogenet. 165, 41-50. https://doi.org/10.1016/j.cancergencyto.2005.08.031
- Canbay E, Eraltan IY, Cercel A, et al (2010). CCND1 and CDKN1B polymorphisms and risk of breast cancer. Anticancer Res, 30, 3093-8.
- Ceschi M, Sun CL, Van Den Berg D, et al (2005). The effect of cyclin D1 (CCND1) G870A-polymorphism on breast cancer risk is modified by oxidative stress among Chinese women in Singapore. Carcinogenesis, 26, 1457-64. https://doi.org/10.1093/carcin/bgi093
- Chen X, Zhao T, Li L, et al (2012). CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population. DNA Cell Biol, 31, 1107-13. https://doi.org/10.1089/dna.2011.1521
- Forsti A, Angelini S, Festa F, et al (2004). Single nucleotide polymorphisms in breast cancer. Oncol Rep, 11, 917-22.
- Grieu F, Malaney S, Ward R, et al (2003). Lack of association between CCND1 G870A polymorphism and the risk of breast and colorectal cancers. Anticancer Res, 23, 4257-9.
- Holley S. L, Matthias C, Jahnke V, et al (2005). Association of cyclin D1 polymorphism with increased susceptibility to oral squamous cell carcinoma. Oral Oncol, 41, 156-60. https://doi.org/10.1016/j.oraloncology.2004.08.005
- Jones R. K, Bulmer J N, Searle RF (1995). Immunohistochemical characterization of proliferation, oestrogen receptor and progesterone receptor expression in endometriosis: comparison of eutopic and ectopic endometrium with normal cycling endometrium. Hum Reprod, 10, 3272-9.
- Justenhoven C, Pierl CB, Haas S, et al (2009). Polymorphic loci of E2F2, CCND1 and CCND3 are associated with HER2 status of breast tumors. Int J Cancer, 124, 2077-81. https://doi.org/10.1002/ijc.24198
- Krippl P, Langsenlehner U, Renner W, et al (2003). The 870G>A polymorphism of the cyclin D1 gene is not associated with breast cancer. Breast Cancer Res Treat, 82, 165-8. https://doi.org/10.1023/B:BREA.0000004372.20461.33
- Lu F, Gladden AB, Diehl JA, (2003). An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res, 63, 7056-61.
- Naidu R, Yip CH, Taib NA (2008). Polymorphisms of HER2 Ile655Val and cyclin D1 (CCND1) G870A are not associated with breast cancer risk but polymorphic allele of HER2 is associated with nodal metastases. Neoplasma, 55, 87-95.
- Noel EE, Yeste-Velasco M, Mao X, et al (2010). The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am J Pathol, 176, 2607-15. https://doi.org/10.2353/ajpath.2010.090780
- Onay UV, Aaltonen K, Briollais L, et al (2008). Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer, 8, 6. https://doi.org/10.1186/1471-2407-8-6
- Solomon DA, Wang Y, Fox SR, et al (2003). Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem, 278, 30339-47. https://doi.org/10.1074/jbc.M303969200
- Sutherland RL, Musgrove EA (2002). Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models. Breast Cancer Res, 4, 14-7.
- Wang L, Habuchi T, Mitsumori K, et al (2003). Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer, 103, 116-20. https://doi.org/10.1002/ijc.10793
- Wang L, Habuchi T, Takahashi T, et al (2002). Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis, 23, 257-64. https://doi.org/10.1093/carcin/23.2.257
- Yaylim-Eraltan I, Ergen A, Gormus U, et al (2009). Breast cancer and cyclin D1 gene polymorphism in Turkish women. In Vivo, 23, 767-72.
Cited by
- Association of Cyclin D1 Variants with Head and Neck Cancer Susceptibility: Evidence from a Meta-analysis vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5645
- The CCND1 G870A polymorphism and susceptibility to bladder cancer vol.35, pp.1, 2014, https://doi.org/10.1007/s13277-013-1021-7
- Genetic association between cyclin D1 polymorphism and breast cancer susceptibility vol.35, pp.12, 2014, https://doi.org/10.1007/s13277-014-2489-5
- Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis vol.35, pp.2, 2014, https://doi.org/10.1007/s13277-013-1154-8
- CCND1 gene polymorphic variants in patients with differentiated thyroid carcinoma pp.1792-1082, 2015, https://doi.org/10.3892/ol.2014.2617
- Influence of CCND1 G870A polymorphism on the risk of HBV-related HCC and cyclin D1 splicing variant expression in Chinese population vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3401-7
- Association of CCND1 Gene c.870G>A Polymorphism with Breast Cancer Risk: A Case-ControlStudy and a Meta-Analysis vol.23, pp.3, 2017, https://doi.org/10.1007/s12253-016-0165-3
- G870A (rs9344) polymorphism and cancer risk in Indian population: meta-analysis and trial sequential analysis vol.38, pp.6, 2018, https://doi.org/10.1042/BSR20180694